Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 3/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6033070 | 0.98 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL297544 | 0.81 | NOS3 (0.44) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL5560254 | 0.81 | ALOX5AP (0.46) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL30868123 | 0.80 | VRK1 (0.31) | FEN1ALOX5AP | |
| SCHEMBL30762204 | 0.80 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL1716472 | 0.80 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL6985744 | 0.78 | NOS3 (0.56) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| Hydrochloric Acid SCHEMBL3038475 | 0.78 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL3643010 | 0.78 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 | |
| SCHEMBL29704112 | 0.78 | NOS3 (0.56) | ALDH1A1SMN1; SMN2KDM4EPOLBNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111087816-A | Preparation method of 2-amino-3-fluoro-5-trifluoromethylpyridine modified GO flame-retardant silicone rubber | 沈阳化工大学 | 2020-05-01 | — | — | CN | claimed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4536350-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | disclosed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118632836-A | Novel aminobenzene derivative having cancer cell growth inhibitory effect and preventive or therapeutic pharmaceutical composition containing the same as active ingredient | 株式会社大熊制药 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023245137-A1 | SLOW SKELETAL TROPONIN ACTIVATORS | CYTOKINETICS, INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-2521553-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-102427810-A | Sulfamoylbenzoic acid derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2424517-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | ALDH1A1 4348/4885SMN1; SMN2 3999/4885KDM4E 3370/4885 |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | ALDH1A1 2879/4885SMN1; SMN2 2132/4885KDM4E 4463/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | ALDH1A1 1000/4885SMN1; SMN2 2361/4885KDM4E 553/4885 |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NOD1, NLRP3, CASP1 | ALDH1A1 1139/4885SMN1; SMN2 2237/4885KDM4E 3952/4885 |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | MKI67, CCNB1, ALDH7A1 | ALDH1A1 211/4885SMN1; SMN2 4237/4885KDM4E 889/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 908/4885SMN1; SMN2 1998/4885KDM4E 981/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | ALDH1A1 1000/4885SMN1; SMN2 2361/4885KDM4E 553/4885 |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | ALDH1A1 1996/4885SMN1; SMN2 1501/4885KDM4E 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.